Research Output per year
Fingerprint Dive into the research topics where Balazs Halmos is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 16 Similar Profiles
Non-Small Cell Lung Carcinoma
Medicine & Life Sciences
Lung Neoplasms
Medicine & Life Sciences
Epidermal Growth Factor Receptor
Medicine & Life Sciences
Mutation
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Protein-Tyrosine Kinases
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Lung
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Publications 1997 2019
Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer
Wang, F., Liu, X., Bartholdy, B. A., Cheng, H. & Halmos, B., Jan 1 2019, In : Translational Cancer Research. 8, 6, p. 2425-2438 14 p.Research output: Contribution to journal › Article
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
RNA Sequence Analysis
Apoptosis
Changes in store for early-stage non-small cell lung cancer
Sandler, J. E., D'Aiello, A. & Halmos, B., Jan 1 2019, In : Journal of Thoracic Disease. 11, 5, p. 2117-2125 9 p.Research output: Contribution to journal › Review article
Non-Small Cell Lung Carcinoma
Biomarkers
Molecular Targeted Therapy
Adjuvant Chemotherapy
Standard of Care
Daily Step Counts: A New Prognostic Factor in Locally Advanced Non-Small Cell Lung Cancer?
Ohri, N., Halmos, B., Bodner, W. R., Cheng, H., Guha, C., Kalnicki, S. & Garg, M., Nov 15 2019, In : International Journal of Radiation Oncology Biology Physics. 105, 4, p. 745-751 7 p.Research output: Contribution to journal › Article
Non-Small Cell Lung Carcinoma
lungs
Radiotherapy
cancer
Disease-Free Survival
Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma
Sukrithan, V., Sandler, J., Gucalp, R. A., Gralla, R. J. & Halmos, B., Jan 1 2019, (Accepted/In press) In : Clinical Lung Cancer.Research output: Contribution to journal › Article
Tumor Burden
Immunotherapy
Carcinoma
Lung
pembrolizumab
8
Citations
(Scopus)
Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)
Halmos, B., Tan, E. H., Soo, R. A., Cadranel, J., Lee, M. K., Foucher, P., Hsia, T. C., Hochmair, M., Griesinger, F., Hida, T., Kim, E., Melosky, B., Märten, A. & Carcereny, E., Jan 1 2019, In : Lung Cancer. 127, p. 103-111 9 p.Research output: Contribution to journal › Article
Safety
Mutation
Lung
Treatment Failure
Incidence